• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 11, 2018

View Archived Issues

Roche piggybacks on Huntington, taps Ionis for 'complementary' partnership

Roche Holding AG issued a vote of confidence in partner Ionis Pharmaceuticals Inc. by tapping the Carlsbad, Calif.-based company for a second alliance, focused on the treatment of complement-mediated diseases. The companies will collaborate on the development of IONIS-FB-LRx, targeting factor B (FB), in a broad range of diseases, beginning with geographic atrophy (GA), the advanced stage of dry age-related macular degeneration (AMD). Read More

ODAC confident on what could be first U.S. Rituxan biosimilar

U.S. biosimilar competition for cancer drug Rituxan is just a step away, after the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously Wednesday to recommend approval of Celltrion Inc.'s CT-P10. Read More

Winner by hair's breadth? Alopecia datasets heading toward phase II readouts

As if to highlight the need for speed in the midstage race in alopecia areata (AA, or hair loss in patches), Wayne, Pa.-based Aclaris Therapeutics Inc. in July gained fast track status from the FDA for the phase II topical JAK1/3 inhibitor ATI-502. Read More

Origimed contributes to first cancer genomics big data platform in China

HONG KONG – Chinese biotech firm Origimed Co. Ltd., of Shanghai, is taking part in building China's first cancer big data platform with two oncology organizations to gather genetic data of the Chinese population. That will give doctors more precise information to diagnose cancer and customize treatment. Read More

Paired with gold nanoparticles, cytokine shown to reduce inflammation, aid muscle repair

Wyss Institute researchers have shown that gold nanoparticles can help extend the half-life of investigational cytokine interleukin 4 (IL-4), which is known to boost anti-inflammatory activity but degrades too quickly when injected alone to produce the desired effect. Read More

'Broadly supportive' briefing docs send Acelrx shares rising ahead of Dsuvia adcom

Briefing documents released ahead of Friday's meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) suggest Acelrx Pharmaceuticals Inc. might have better luck the second time around with its sublingual 30-mcg tablet version of sufentanil given by way of a non-invasive, single-dose applicator. Read More

Other news to note

Beigene, Ltd., of Beijing, said China's State Medical Insurance Administration has included Vidaza (azacitidine for injection) on its national reimbursement drug list. The nucleoside metabolic inhibitor was approved in China for patients with intermediate-2/high-risk myelodysplastic syndrome, acute myeloid leukemia with 20 percent to 30 percent bone marrow blasts and chronic myelomonocyte leukemia. It is marketed in China under an exclusive license from Celgene Corp., of Summit, N.J. Read More

Financings

Audentes Therapeutics Inc., of San Francisco, said it intends to offer $150 million of its common stock in an underwritten public offering and also grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its common stock. Read More

Appointments and advancements

Insys Therapeutics Inc., of Phoenix, appointed Mark Nance chief legal officer and general counsel. Read More

Regulatory front

President Donald Trump has signed into law bills S. 2553 and S. 2554 banning the insurance gag clauses that have kept pharmacists from letting patients know that paying out of pocket might be cheaper than their copay for a prescription drug.  Read More

Clinical data for Oct. 10, 2018

Read More

Regulatory actions for Oct. 10, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe